Gilead signs deals with Indian companies for low-cost HIV drug
(Reuters) - Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.
Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.
Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.
(Reporting by Shailesh Kuber; Editing by Viraj Nair)
- Tweet this
- Share this
- Digg this
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- California lawmakers end session with bills on plastic bags, gun control
- India nears $2.5 billion deal for Boeing military helicopters
- CBI charges Dayanidhi Maran, Malaysian tycoon in telecoms scandal
- Saudi king warns of terrorism threat to U.S., Europe
The West African state of Senegal became the fifth country to be hit by the world's worst Ebola outbreak on Friday, while riots broke out in neighbouring Guinea's remote southeast where infection rates are rising fast. Full Article